Todd C. Davis, serving as a director at Pelthos Therapeutics Inc. (NASDAQ: PTHS), has executed a substantial acquisition of the biotechnology company's equity. On June 11, 2026, Mr. Davis purchased common stock through two separate direct transactions. The aggregate value of these acquisitions reached $999,983. The price per share for these transactions varied between $27.8046 and $28.7261, indicating a strategic entry point into the company's shares.
The first transaction involved the acquisition of 35,445 shares. These shares were purchased at a weighted average price of $27.8046 per share. This acquisition was not executed as a single block but rather through multiple trades, with prices fluctuating between $27.63 and $28.49. In a subsequent, separate transaction, Mr. Davis acquired an additional 503 shares. These shares were bought at a weighted average price of $28.7261 per share, with the execution prices for this specific block ranging from $28.72 to $28.94.
Following these recent purchases, Mr. Davis's direct holdings in Pelthos Therapeutics common stock total 75,834 shares. The insider buying activity occurs while the stock is currently trading at $26.50. This market price is positioned below InvestingPro’s Fair Value assessment of $32.60, a discrepancy that may suggest the shares are currently undervalued relative to internal metrics. Despite recent market volatility, PTHS has delivered a 124% return over the past year, indicating significant price appreciation in the preceding twelve-month period.
In addition to direct holdings, the filing highlights indirect ownership structures. Ligand Pharmaceuticals Incorporated holds 1,500,000 shares of Pelthos Therapeutics common stock indirectly. Mr. Davis serves as the Chief Executive Officer and a board member of Ligand Pharmaceuticals Inc. However, he explicitly disclaims beneficial ownership of these Ligand-held shares, except to the extent of his pecuniary interest therein.
The insider purchase activity coincides with recent fundamental developments at Pelthos Therapeutics. The company recently announced its first-quarter 2026 earnings, which revealed a notable miss on earnings per share (EPS) expectations. The reported actual EPS was -3.09 USD, a figure significantly below the forecasted -0.51 USD. This discrepancy resulted in a surprise of -505.88%. Despite this substantial earnings miss, the company’s revenue growth and product performance have contributed to maintaining investor confidence. The earnings report highlights Pelthos’ ongoing business developments and potential future growth. Analysts have yet to provide any upgrades or downgrades following this announcement. The market’s reaction indicates that investors may be focusing on other aspects of the company’s performance. These recent developments continue to shape the outlook for Pelthos Therapeutics.